Submission Information
Here's what to know about submitting your research

Abstract Submission is Now Open!

Submitting an Abstract

Approximately 25 percent of the abstracts submitted will be eligible for oral presentation based on the review scores. All accepted abstracts will be published in a May supplement to ASGCT's journal Molecular Therapy.

Associate Members who are first and presenting abstract authors can register for the meeting for free.

Formatting Guidelines

  • Abstracts have a maximum limit of 3,500 characters. This includes the abstract title, abstract body, graphics, tables, and all author information. Spaces are not included in the character limit.

  • Figures and tables each use approximately 320 of your 3,500 total characters. 

  • ASGCT has no required format for the body of an abstract. Abstracts may be written in one block of text or divided into sections such as: Introduction, Methods, Results, and Conclusions. This is strictly the author's preference.

  • Authors should be cautious in using institutional references in the body of the abstract. Do not put author names and/or affiliations in the body. Abstracts which include reference to authors or institutions will not be reviewed.

Notification of Abstract Acceptance

Notification regarding acceptance of abstracts will be delivered via email on April 11, 2022. The official acceptance letter, which includes all details of a presentation including date, time and location, will be posted online through the abstract submission website. Meritorious Abstract Travel Awards, Excellence in Research Awards, and Underrepresented Minority Travel Awards acceptance and letters will also be sent at this time.

Acceptance of Presentation

All notified abstract presenters are required to accept their presentation as instructed in their notification email. This can be done online through the abstract submission site.

Abstract Questions

For all questions regarding the abstract submission process, please contact Coe-Truman Technologies’ Technical Support by phone at 1-217-398-1792 or by email at

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.